Clinical trial · Interventional
ERAS for Patients Received Neoadjuvant Chemotherapy
Enhanced Recovery After Surgery Programs for Patients Received Neoadjuvant Chemotherapy With Locally Advanced Gastric Cancer: a Randomized Controlled Clinical Trial
NCT03272984CI-TRIAL-00029445ERASNACcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients received neoadjuvant chemotherapy with locally advanced gastric caner undergo the enhanced recovery after surgery (ERAS) programs or the standard cares (SC) programs.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ERAS group | Procedure | — | UNRESOLVED |
| SC group | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- ERAS group
- description
- Patients will undergo the ERAS programs.
- interventionNames
- Procedure: ERAS group
- type
- OTHER
- label
- SC group
- description
- Patients will undergo the SC group.
- interventionNames
- Procedure: SC group
Primary outcomes (1)
- measure
- Postoperative length of stay
- timeFrame
- 1 month
- description
- Postoperative length of stay
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients received neoadjuvant chemotherapy with locally advanced gastric cancer. 2. Age older than 18 and younger than 75 years. 3. American Society of Anesthesiologists (ASA) class: I-III. 4. Participants can describe the symptom objectively and cooperate actively. 5. Written informed consent. Exclusion Criteria: 1. Patients allergic to oxaliplatin, tegafur gimerac etc. 2. Patients with ischemic heart disease, cerebrovascular disease and peripheral vascular disease, or cardiac function \> II (NYHA) 3. Patients with complications (bleeding, perforation and obstruction) caused by gastric cancer. 4. Patients with severe liver and renal dysfunction (Child - Pugh ≥ 10; Cr \< 25 ml/min). 5. Patients who require simultaneous surgery for other diseases. 6. Patients who received upper abdominal surgery previously. 7. Pregnant or breast-feeding women.
References
Publications (0)
Data not yet available
No reference posted for this study.